On Friday, CVS Health Inc (NYSE:CVS) released data from the CVS Weight Management program, in which participants achieved more than 15% weight loss on average. This included existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.
Results are derived from a population of 265,000 members from 2023-2024.
Also Read: CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock
The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients’ plan members trying a lifestyle-first approach, as well as additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s.
GLP-1 products from Novo Nordisk A/S (NYSE:NVO) and Eli Lilli And Co (NYSE:LLY) have gained substantial traction. The CVS Weight Management program provides one-on-one support from a dedicated registered dietitian in a virtual setting, including personalized nutrition planning.
The program can integrate into a member’s existing pharmacy benefit with plan sponsors’ direction.
CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on GLP-1 medications for weight loss than clients who did not adopt the program.
The program also has a lasting impact, with 92% of participating plan members expressing satisfaction after six months.
As of February 1, 2025, the CVS Weight Management program is now available to over 3.5 million CVS Caremark plan members.
Despite FDA prescription drug labeling recommendations to take GLP-1’s in combination with diet and physical activity, 70% of members were using a weight management drug without any lifestyle or nutrition support before enrolling in the CVS Weight Management program.
- Before program enrollment, nearly 30% of members had lost less than 1% of their body weight on anti-obesity medication. These same members lost, on average, 11.7% of body weight after enrollment.
- The program accelerated weight loss and delivered an average of 20% weight loss for those with moderate success before enrollment.
- Members who chose to discontinue anti-obesity medication and retain lifestyle support maintained 94% of their weight loss after 6 months.
Price Action: CVS stock is up 1.33% at $66.64 at the last check Friday.
Read Next:
- Perspective Therapeutics’ Cancer-Focused Radiotherapy Portfolio Has Upside Potential, Says Analyst
Photo via Shutterstock
